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42%, from 85.5 per 10,000 admissions in the pre-intervention phase to 49.0 per 10,000 admissions in the Avoid-Heparin phase (p<0.001). The annual rate of patients with a positive HIT assay decreased 63% from 16.5 to 6.1 per 10,000 admissions (p<0.001); adjudicated HIT decreased 79% from 10.7 to 2.2 per 10,000 admissions (p<0.001); and HIT with thrombosis decreased 91% from 4.6 to 0.4 per 10,000 admissions (p<0.001). Hospital HIT-related expenditures decreased by $266,938 per year in the Avoid-Heparin phase. To our knowledge, this is the first study demonstrating the success and feasibility of a hospital-wide HIT prevention strategy.
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INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is a transient, limb-and life-threatening, immunemediated adverse drug reaction in patients exposed to heparin. HIT is characterised by immunoglobulin G antibodies against platelet factor 4 (PF4)-heparin complexes which trigger a highly prothrombotic state through intravascular platelet aggregation, intense platelet activation and excessive thrombin generation. 1 The diagnosis of HIT is based on a significant fall in the platelet count with or without venous or arterial thrombosis combined with serologic evidence of HIT antibodies in patients exposed to unfractionated heparin (UFH) or low molecular weight heparin (LMWH). [2] [3] [4] Treatment of HIT involves discontinuing all forms of heparin and administration of an alternative, non-heparin anticoagulant. 4 HIT occurs in up to 5% of patients exposed to UFH, one of the drugs most commonly prescribed to hospital patients. [5] [6] [7] The recognition and evaluation of suspected HIT is often delayed. 4, 6, 8, 9 Even with prompt cessation of heparin and implementation of a HIT-safe anticoagulant, thromboembolic complications occur in 20-50% of patients, and death or limb amputation occurs in approximately 5-10%. 4, 8, [10] [11] [12] [13] [14] In addition to the significant disease burden, HIT is associated with substantial resource use. An economic analysis study from our center reported that the direct costs to the hospital for HIT were $456,787 over a one-year period. 15 Although improved surveillance and management may reduce the burden of HIT, comprehensive initiatives to prevent HIT are likely to be more effective in decreasing the morbidity, mortality and costs associated with HIT. It is well-established that LMWH is associated with a five to 10-fold lower risk of HIT than UFH. [16] [17] [18] [19] [20] [21] Furthermore, thrombosis is less likely to occur when HIT is triggered by LMWH than by UFH. 21 Therefore, reducing patient exposure to UFH and substitution of UFH with LMWH may improve patient safety
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 4 related to HIT. The aim of this quality improvement study was to evaluate the impact of an Avoid-Heparin intervention on the incidence of HIT, its clinical consequences and associated costs over a 10-year period.
METHODS

Study Setting
In 2005, a multidisciplinary committee was created to develop strategies to reduce the burden of HIT at Sunnybrook Health Sciences Centre in Toronto, Canada. Sunnybrook is a tertiarycare, university-affiliated hospital with over 450 adult acute care beds, a large Cardiac Surgery program and a Thromboembolism service that manages all cases of established HIT. Removal of UFH stores from most nursing units Most care providers were not aware that heparin was being replaced by LMWH as part of an Avoid-Heparin initiative and none were aware that this practice change was being studied.
There were also no efforts to educate staff about HIT nor were there any changes in the approach to its diagnosis. 
Case Definitions
Explicit definitions of the various study groups were established a priori (Table S1) . All patients with a positive HIT ELISA were adjudicated by the investigators using information available in the medical record. Adjudicated HIT was defined as suspected HIT with:
1. positive SRA or 2. positive HIT ELISA, SRA not done, and diagnosed and treated as HIT by the Thromboembolism service at the time of the suspected HIT and confirmed at the independent adjudication review using standardized criteria outlined in Table S1 .
HIT negative was defined as suspected HIT with: Cases were labeled HIT uncertain if the HIT ELISA was positive but the diagnosis could not be confirmed or ruled out at adjudication. In the small number of cases with a positive HIT ELISA that were not seen by the Thromboembolism service or when the adjudication process yielded a different HIT status for a patient than that made at the time of clinical suspicion, the case was re-reviewed and consensus among investigators was used based on the diagnostic criteria in Table S1 . HIT with thrombosis (HITT) was defined as HIT positive with proven venous and/or arterial thrombosis less than seven days before or up to 30 days after the date of suspected HIT. For thrombotic events that occurred less than seven days before the date of suspected HIT, each case was carefully reviewed to determine the probable sequence of events. Patients with thromboembolism prior to heparin exposure who subsequently developed HIT were not labelled as HITT. Major bleeding was defined as overt bleeding in a For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 7 patient receiving a HIT-safe anticoagulant and meeting at least one of the following criteria: requiring two or more units of packed red blood cells, prolonging hospital admission, fatal or life-threatening bleeding at a critical site such as intracranial or retroperitoneal, or bleeding requiring an intervention such as endoscopic or endovascular treatment or surgery.
22
Anti-PF4-Heparin HIT ELISA
Throughout the study period, the Special Coagulation Laboratory detected polyspecific PF4-heparin antibodies using the Genetic Testing Institute PF4 ELISA (GTI Diagnostics, Waukesha, WI). 23 An OD value of >0.4 was used as the threshold for a positive test as suggested by the manufacturer and locally validated by the laboratory.
Outcomes
The rates of suspected HIT, positive HIT ELISA, adjudicated HIT, and HITT in the preintervention and the Avoid-Heparin phases were compared. Annual rates per 10,000
admissions were determined using admission data from the Health Data Resources Department. The additional costs for suspected HIT, adjudicated HIT and HITT were based on a published cost-analysis done at our institution and the observed events in the present study. 15 HIT-related costs in the pre-intervention phase were compared to those in the AvoidHeparin phase.
Statistical Analyses
Statistical analyses were performed with SPSS 16.0 (SPSS, Chicago, IL). Continuous variables were summarized as medians with interquartile ranges (IQR), because of nonnormal distributions. The Mann-Whitney U test was used to detect differences in continuous Demographic and clinical characteristics of HIT positive patients in the pre-intervention phase (n=53) and the Avoid-Heparin phase (n=26) were similar ( Table 1) . Approximately 60% of patients with HIT in both phases were admitted under the cardiovascular surgery service.
RESULTS
The durations of UFH/LMWH exposure and median lengths of hospital stay were similar between the groups. The median HIT ELISA OD among patients with HIT was significantly higher in the Avoid-Heparin phase (2.79, IQR 1.76-2.89) compared with the pre-intervention phase (2.07, IQR 1.21-2.40, p=0.001). While the overall use of LMWH increased 4-fold (based on doses purchased) over the study period, the annual rate of HIT associated with LMWH remained constant at 0.9 cases per 10,000 admissions in the pre-intervention and Avoid-Heparin phases (p=0.78, Figure 3 ). There were no significant differences in patient age, gender, duration of UFH/LMWH exposure, or length of hospital stay among patients with (Table S3) . HIT was reduced 77% in cardiovascular surgery, 77% in other surgery, 75% in cardiology patients, and 62% in medical patients ( Figure S1 ).
Comparison of HIT with and without Thrombosis
Patients with HIT in the pre-intervention phase more frequently developed HITT (43%) than patients with HIT in the Avoid-Heparin phase (19%, p=0.035, Table 2 Table S4) .
HIT-Related Treatment & Costs
The mean number of suspected HIT cases per year decreased from 141.3 in the preintervention phase to 96.0 in the Avoid-Heparin phase ( Table S5 ). The mean number of patients per year with a positive HIT ELISA, adjudicated HIT and HITT per year decreased from 27.3 to 11.8, 17.7 to 4.3, and 7.7 to 0.8, respectively, in the pre-intervention and AvoidHeparin phases. HIT was treated with lepirudin and danaparoid more frequently in the preintervention phase while fondaparinux and argatroban were used more frequently in the Avoid-Heparin phase (Table S6) . Based on a published study from our institution 15 , the Table 3) .
DISCUSSION
Following the implementation of a hospital-wide quality improvement program based on replacing UFH with LMWH, we observed a dramatic reduction in the burden of HIT with a 42% decrease in suspected HIT, 63% decrease in patients with positive HIT ELISA, 79% decrease in adjudicated HIT, 91% decrease in HITT, and 83% decrease in HIT-related costs of care. Although the greatest overall impact of the program was in cardiac surgery, the HIT burden was also reduced in other surgical and medical patients. The heparin avoidance strategy that we utilized was not complex or costly, and would be feasible in other centers.
A lower risk of HIT and its thrombotic complications among patients exposed to LMWH compared to UFH has been previously demonstrated. 7, [16] [17] [18] [19] [20] [21] LMWH is thought to induce a less robust antibody response when complexed to PF4 than observed with UFH-PF4 due to stoichiometric differences of heparin-PF4 complexes. 24 Despite the four-fold increase in LMWH use over the study period, the incidence of HIT in patients who received LMWH was low and remained stable over the 10-year study period. Others have also demonstrated stable rates of HIT despite substantial increases in LMWH use. 7, 25 Our results expand on observations from studies with limited target groups and focused interventions. Replacement of UFH with LMWH in orthopedic surgery has been shown to reduce both venous thromboembolism and HIT.
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The literature has emphasized early recognition and treatment of HIT, while its prevention has been largely overlooked. 27 Guidelines recommend platelet count monitoring 4 However, adherence to platelet count monitoring, testing for HIT antibodies if thrombocytopenia develops and switching to HIT-safe anticoagulation when HIT is suspected is challenging, resource intensive and may not reduce the adverse consequences of HIT. 6, 9, [28] [29] [30] Previous studies have demonstrated that over half of the thrombotic events in HIT occur following the cessation of heparin without additional treatment of HIT. 8, 11 In our study, we observed that more than half of the HITT cases [17/31] had the thromboembolic event diagnosed after the diagnosis of HIT and while on HIT-safe anticoagulation, emphasising not only the need for early recognition and treatment, but also the need to prevent HIT. We observed that patients with HIT in the Avoid-Heparin phase were two times less likely to develop HITT. A previous study from our center demonstrated that the incremental hospital cost of suspected and confirmed cases of HIT was $456,787 over a one-year period and 90% of these costs were attributed to HITT. 15 Together, these findings suggest that a hospital-wide, Avoid-Heparin program leads to a substantial reduction in the morbidity, mortality and institutional costs associated with HIT.
Consistent with published literature, the positive predictive value of the HIT assay was 51% (89/175) over the entire study period. 31, 32 Among the 84 patients with a HIT ELISA OD between 0.4 and 1.0, only 17% were found to have HIT. False positive HIT assays were found with OD values as high as 2.4, emphasizing that HIT cannot be diagnosed by laboratory evidence alone. 4, 33 The median HIT ELISA OD in patients with HIT was higher in the Avoid-Heparin phase than the pre-intervention phase (2.79 vs 2.07, respectively, Table   1 ). Because the likelihood of true HIT increases with increasing OD, this could suggest that there were more false-positive diagnoses in the pre-intervention phase. Recently, Chan et al 34 reported that the HIT ELISA OD cut-off could be increased from 0.4 to 1.00 to improve the positive predictive value without losing sensitivity.
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This study has limitations that warrant consideration. It was conducted at a single tertiary care hospital whose HIT-related practices may differ from other centers. Since there is no reference standard for the diagnosis of HIT and only 40% of patients with a positive HIT ELISA had an SRA, we cannot determine the accuracy of our case allocation in all patients.
However, the observations in this study were based on a review of all cases with suspected HIT over a 10-year period and therefore reflect routine clinical practice. We attempted to minimise potential bias in adjudication of HIT by establishing case definitions a priori. In only 5 cases did the final case allocation after adjudication differ from that made by the clinical team at the time of suspected HIT. Although this study's findings are based on a prospective quality improvement project, patient data were abstracted and cases were adjudicated retrospectively. This could have led to possible bias in case definition by the investigators. We were unable to calculate the 4Ts score for patients with suspected HIT retrospectively. 35, 36 However, patient characteristics in the pre-intervention and Avoid-Heparin phases were similar, and we were unable to identify any other factors that could have accounted for the dramatic reductions in suspected HIT, adjudicated HIT and HITT during the study period. The long duration of observation showing a sudden and sustained reduction in HIT after implementation of the Avoid-Heparin strategy was designed to demonstrate that this was not a random observation. Finally, we were unable to determine hospital-wide, patient-level data on exposures to UFH and LMWH; however, LMWH use increased more than four-fold based on overall changes in drug utilization over the study period. Clearly, the cost reductions we observed are specific to our center and will differ in other centers depending on overall HIT burden and the local costs of investigating and treating HIT.
Our findings cannot be explained by an overall reduction in the number of admissions or length of stay over the study period. In fact, total patient admissions increased 21% while the
was at the discretion of the patient's clinical service and was not influenced by the investigators or the Thromboembolism team. Moreover, the greater reduction in cases of HIT (79%) and HITT (91%) than in suspected HIT (42%) suggests a decrease in the actual disease burden rather than a biased increase in diagnostic threshold (Figure 1) . The temporal pattern of this study's findings show that the reduction in HIT was not gradual but occurred in 2006 and was maintained beyond the intervention year (Figure 2) , suggesting it is unlikely that secular trends in decreased UFH utilisation could explain these findings. The study's observations can also not be accounted for by use of direct oral anticoagulants since rivaroxaban was approved only for hip and knee arthroplasty thromboprophylaxis in 2009 and dabigatran was approved for atrial fibrillation in 2011.
Conclusions
The introduction of a hospital-wide, Avoid-Heparin program led to a dramatic decrease in the burden of suspected HIT, diagnosed HIT and HITT, as well as in the costs of HIT care. To our knowledge, this is the first study demonstrating the success of a HIT prevention strategy. Our findings suggest that a highly feasible heparin avoidance intervention can improve patient safety and reduce hospital costs.
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